Previous 10 | Next 10 |
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2022 Earnings Conference Call November 3, 2022 4:30 AM ET Company Participants Dolly Vance - Senior Advisor, Legal & Corporate Affairs Raul Rodriguez - President and CEO Wolfgang Dummer - Executive Vice President and Chie...
The following slide deck was published by Rigel Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Rigel Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation
Rigel Pharmaceuticals press release ( NASDAQ: RIGL ): Q3 GAAP EPS of -$0.11 beats by $0.03 . Revenue of $22.4M (+4.2% Y/Y) misses by $0.21M . FDA review ongoing for olutasidenib NDA; preparations underway for potential launch Third quarter TAVALISSE ®...
Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update PR Newswire FDA review ongoing for olutasidenib NDA; preparations underway for potential launch Third quarter TAVALISSE ® net product sales of $19.2 million and total...
Rigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition PR Newswire Updated interim analysis from Phase 2 registrational study highlights 35% of mIDH1 R/R AML patients who received olutasidenib achie...
Development-stage biotech Rigel Pharmaceuticals ( NASDAQ: RIGL ) traded higher on Wednesday even after the company said that a Phase 3 trial for its investigational COVID-19 therapy, fostamatinib, did not meet the main goal with statistical significance. The 280-patient ...
Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients PR Newswire SOUTH SAN FRANCISCO, Calif. , Nov. 1, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announc...
Summary RIGL hoped to expand the label of its drug Tavalisse (fostamatinib), but the failure of the drug in phase 3 appeared to scupper its chances. RIGL sought guidance to see if a reanalysis of the failed phase 3 study might be well received, but it doesn't appear it was. Th...
Rigel Announces Conference Call and Webcast to Report Third Quarter 2022 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , Oct. 27, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it ...
Rigel Pharmaceuticals ( NASDAQ: RIGL ) is eliminating 16% of its workforce -- 30 positions -- in the wake of a decision to not file supplemental New Drug Application (sNDA) for fostamatinib for warm autoimmune hemolytic anemia. Shares are down 12% in after-hou...
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
2024-06-27 09:02:05 ET Rigel Pharmaceuticals (RIGL) announced stock split at a ratio of 1-for-10 on 2024-06-27 ... Full story available on KlickAnalytics.com
Rigel Announces Reverse Stock Split PR Newswire SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common st...
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application PR Newswire GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmac...